Literature DB >> 6861339

Determination of nifedipine in serum or plasma by reversed-phase liquid chromatography.

P R Bach.   

Abstract

Therapeutic concentrations of nifedipine in serum or plasma were measured by reversed-phase liquid chromatography, with detection by ultraviolet absorbance at 235 nm. In the procedure a disposable reversed-phase extraction column is used. A 1-mL sample is required. The method is sensitive to 3 micrograms of nifedipine per liter and the standard curve is linear to at least 400 micrograms/L. Coefficients of variation at 100 micrograms/L were 2.2% within-run, 2.8% between-run. The method has been used to determine nifedipine in patients involved in a test of its efficacy in treating muscular dystrophy.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6861339

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  5 in total

Review 1.  Nifedipine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy, in ischaemic heart disease, hypertension and related cardiovascular disorders.

Authors:  E M Sorkin; S P Clissold; R N Brogden
Journal:  Drugs       Date:  1985-09       Impact factor: 9.546

2.  The first pass metabolism of nifedipine in man.

Authors:  D G Waller; A G Renwick; B S Gruchy; C F George
Journal:  Br J Clin Pharmacol       Date:  1984-12       Impact factor: 4.335

3.  Pharmacokinetics of nimodipine in patients with aneurysmal subarachnoid haemorrhage.

Authors:  E Vinge; K E Andersson; L Brandt; B Ljunggren; L G Nilsson; S Rosendal-Helgesen
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

Review 4.  Nifedipine. Relationship between pharmacokinetics and pharmacodynamics.

Authors:  C H Kleinbloesem; P van Brummelen; D D Breimer
Journal:  Clin Pharmacokinet       Date:  1987-01       Impact factor: 6.447

Review 5.  Clinical pharmacokinetics of verapamil, nifedipine and diltiazem.

Authors:  H Echizen; M Eichelbaum
Journal:  Clin Pharmacokinet       Date:  1986 Nov-Dec       Impact factor: 6.447

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.